Myriad Genetics (FRA:MYD) Cyclically Adjusted PB Ratio: (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MYD Myriad Genetics Inc FRA:MYD
58 GF Score
Price €4.33
GF Value €12.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Myriad Genetics  (FRA:MYD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Myriad Genetics Cyclically Adjusted PB Ratio Related Terms


Myriad Genetics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Cyclically Adjusted PB Ratio Chart

Myriad Genetics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.19 1.07 1.39 1.00 0.47

Myriad Genetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.54 0.47 0.34 0.00

FRA:MYD vs FLGT, CSTL, BDSX: Cyclically Adjusted PB Ratio Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted PB Ratio falls into.


FRA:MYD
58GF Score
Myriad Genetics Inc FRA:MYD
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Myriad Genetics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Myriad Genetics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.783/333.9520*333.9520
=2.783

Current CPI (Jun. 2026) = 333.9520.

Myriad Genetics Quarterly Data

Book Value per Share CPI Adj_Book
201609 9.581 241.428 13.253
201612 10.202 241.432 14.112
201703 10.273 243.801 14.072
201706 9.998 244.955 13.630
201709 10.559 246.819 14.287
201712 11.131 246.524 15.079
201803 11.010 249.554 14.734
201806 11.714 251.989 15.524
201809 12.645 252.439 16.728
201812 12.779 251.233 16.987
201903 13.044 254.202 17.136
201906 13.111 256.143 17.094
201909 13.114 256.759 17.057
201912 13.013 256.974 16.911
202003 11.749 258.115 15.201
202006 10.915 257.797 14.139
202009 10.266 260.280 13.172
202012 9.605 260.474 12.315
202103 9.585 264.877 12.085
202106 9.641 271.696 11.850
202109 10.330 274.310 12.576
202112 10.706 278.802 12.824
202203 10.784 287.504 12.526
202206 11.120 296.311 12.533
202209 11.443 296.808 12.875
202212 10.298 296.797 11.587
202303 9.571 301.836 10.589
202306 8.286 305.109 9.069
202309 7.803 307.789 8.466
202312 7.989 306.746 8.698
202403 7.726 312.332 8.261
202406 7.568 314.175 8.044
202409 7.245 315.301 7.674
202412 7.334 315.605 7.760
202503 7.072 319.799 7.385
202506 3.614 322.561 3.742
202509 3.414 324.800 3.510
202512 3.361 324.054 3.464
202603 3.092 330.213 3.127
202606 2.783 333.952 2.783

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Myriad Genetics (FRA:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €4.33 is trading 64.7% below its estimated GF Value™ of €12.24. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for FRA:MYD:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €12.24 vs. price of €4.33 (64.7% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UK
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
58GF Score

Get the complete analysis for FRA:MYD

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.33
Price
€12.24
GF Value